ITDts is a novel selective TGF-β pathway-selective inhibitor that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. Racemic ITDts is 2-fold selective over the closely related Activin A signaling pathway. ITDts stimulates embryonic stem cells to differentiate into cardiomyocytes (IC50 0.7 µM) by degrading the receptor and inhibiting intracellular signaling. ITDts has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITDts is chemically and metabolically stable and is non-cytotoxic. ITDts can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.

ITDts is a novel selective TGF-β pathway-selective inhibitor that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. Racemic ITDts is 2-fold selective over the closely related Activin A signaling pathway. ITDts stimulates embryonic stem cells to differentiate into cardiomyocytes (IC50 0.7 µM) by degrading the receptor and inhibiting intracellular signaling. ITDts has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITDts is chemically and metabolically stable and is non-cytotoxic. ITDts can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.